Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 1

Interventions

Fluorouracil 309 Oxaliplatin 260 Leucovorin 234 Capecitabine 198 Irinotecan 147 Gemcitabine 128 Cisplatin 126 Bevacizumab 119 Radiotherapy 72 Paclitaxel 64 Folfox protocol 56 Cetuximab 56 Drug Therapy 46 Sorafenib 45 Docetaxel 42 S 1 (combination) 40 Chemotherapy, Adjuvant 38 Neoadjuvant Therapy 37 pembrolizumab 36 130-nm albumin-bound paclitaxel 28 Surgical Procedures, Operative 27 regorafenib 25 lenvatinib 24 XELOX 24 Panitumumab 24 Radiation 23 Nivolumab 23 atezolizumab 22 Carboplatin 22 trifluridine tipiracil drug combination 21

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × orantinib × Gastrointestinal × Clear all

NCT01465464 2019-08-07

ORIENTAL

Taiho Pharmaceutical Co., Ltd.

Phase 3 Terminated

888 enrolled 12 charts

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡